Home LiteratureArticle Details
PMID: 18097155 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Biomarkers for early detection of Alzheimer pathology.

Neuro-Signals ·Vol. 16 ·No. 1 ·2008-00-00 ·Pages 11-8

Clark CM, Davatzikos C, Borthakur A, Newberg A, Leight S, Lee VM, Trojanowski JQ

Abstract

The increasing prevalence of Alzheimer's disease and the devastating consequences of late-life dementia motivates the drive to develop diagnostic biomarkers to reliably identify the pathology associated with this disorder. Strategies to accomplish this include the detection of altered levels of tau and amyloid in cerebrospinal fluid, the use of structural MRI to identify disease-specific patterns of regional atrophy and MRI T(1)rho to detect disease-related macromolecular protein aggregation, and the direct imaging of amyloid deposits using positron emission tomography and single photon emission computerized tomography. Success will facilitate the ability to reliably diagnose Alzheimer's disease while the symptoms of brain failure are mild and may provide objective measures of disease-modifying treatment efficacy.

MeSH Terms
Alzheimer Disease/diagnosis,metabolism Biomarkers/metabolism Early Diagnosis Humans
Chemicals
Biomarkers
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Clark C M
Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA. [email protected]
Davatzikos C
Borthakur A
Newberg A
Leight S
Lee V M-Y
Trojanowski J Q
References (35)
35 references, click to expand
  1. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease.
    Brain Res. 2004 Oct 29;1025(1-2):98-105 PMID: 15464749
  2. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?
    Arch Neurol. 2003 Dec;60(12):1696-702 PMID: 14676043
  3. In vivo measurement of T1rho dispersion in the human brain at 1.5 tesla.
    J Magn Reson Imaging. 2004 Apr;19(4):403-9 PMID: 15065163
  4. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study.
    Ann Neurol. 2006 Jul;60(1):145-7 PMID: 16802294
  5. MRI predictors of risk of incident Alzheimer disease: a longitudinal study.
    Neurology. 2005 May 10;64(9):1520-4 PMID: 15883311
  6. Differential associations between entorhinal and hippocampal volumes and memory performance in older adults.
    Behav Neurosci. 2003 Dec;117(6):1150-60 PMID: 14674836
  7. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.
    Exp Neurol. 2000 Nov;166(1):201-3 PMID: 11031097
  8. Alzheimer disease in the US population: prevalence estimates using the 2000 census.
    Arch Neurol. 2003 Aug;60(8):1119-22 PMID: 12925369
  9. Cerebrospinal fluid protein biomarkers for Alzheimer's disease.
    NeuroRx. 2004 Apr;1(2):213-25 PMID: 15717022
  10. Biological markers and the treatment of Alzheimer's disease.
    J Mol Neurosci. 2001 Oct;17(2):119-25 PMID: 11816785
  11. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease.
    Neurobiol Aging. 2001 Sep-Oct;22(5):747-54 PMID: 11705634
  12. Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging.
    Neuroimage. 2003 Feb;18(2):525-41 PMID: 12595205
  13. One-year age changes in MRI brain volumes in older adults.
    Cereb Cortex. 2000 May;10(5):464-72 PMID: 10847596
  14. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
    Brain. 2006 Nov;129(Pt 11):2856-66 PMID: 16854944
  15. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects.
    Neurology. 2002 Aug 27;59(4):627-9 PMID: 12196665
  16. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Lancet Neurol. 2006 Mar;5(3):228-34 PMID: 16488378
  17. CSF markers for incipient Alzheimer's disease.
    Lancet Neurol. 2003 Oct;2(10):605-13 PMID: 14505582
  18. F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain.
    Nucl Med Biol. 2005 Nov;32(8):799-809 PMID: 16253804
  19. SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study.
    Neurology. 2001 Apr 10;56(7):950-6 PMID: 11294935
  20. Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies.
    Ann Intern Med. 2003 Mar 4;138(5):400-10 PMID: 12614093
  21. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease.
    Mol Neurobiol. 2001 Aug-Dec;24(1-3):87-97 PMID: 11831556
  22. Deformable registration of cortical structures via hybrid volumetric and surface warping.
    Neuroimage. 2004 Aug;22(4):1790-801 PMID: 15275935
  23. Qualitative assessment of cerebral atrophy on MRI: inter- and intra-observer reproducibility in dementia and normal aging.
    Eur Neurol. 1997;37(2):95-9 PMID: 9058064
  24. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics.
    Nat Rev Drug Discov. 2007 Apr;6(4):295-303 PMID: 17347655
  25. Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus. Dementia of the Alzheimer type.
    Neurology. 2000 Dec 12;55(11):1636-43 PMID: 11113216
  26. Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy.
    Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14079-84 PMID: 10570201
  27. Differential rates of regional brain change in callosal and ventricular size: a 4-year longitudinal MRI study of elderly men.
    Cereb Cortex. 2002 Apr;12(4):438-45 PMID: 11884358
  28. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.
    Neurology. 2007 Feb 13;68(7):501-8 PMID: 17065593
  29. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.
    JAMA. 2001 Nov 7;286(17):2120-7 PMID: 11694153
  30. Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease." Biochemical biomarkers of late-life dementia.
    Alzheimers Dement. 2006 Oct;2(4):287-93 PMID: 19595902
  31. In vivo measurement of plaque burden in a mouse model of Alzheimer's disease.
    J Magn Reson Imaging. 2006 Nov;24(5):1011-7 PMID: 17036339
  32. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.
    Acta Neurol Scand Suppl. 2003;179:47-51 PMID: 12603251
  33. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease.
    Neurology. 2006 Aug 8;67(3):446-52 PMID: 16894106
  34. Global prevalence of dementia: a Delphi consensus study.
    Lancet. 2005 Dec 17;366(9503):2112-7 PMID: 16360788
  35. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease.
    Neurology. 2006 Nov 14;67(9):1575-80 PMID: 16971697
Article Info
Journal
Neuro-Signals
Abbr.
Neurosignals
ISSN
1424-862X
DOI
10.1159/000109754
Email
[email protected]
Published
2008-00-00
Epub
2007-00-05
Pages
11-8
Language
English
Region
Switzerland
NLM ID
101134359
PMCID
PMC2866153
Subset
IM
Grants
NIA NIH HHS · P30 AG010124 · United States
NIA NIH HHS · AG10124 · United States
NIA NIH HHS · U19 AG010483 · United States
NCRR NIH HHS · P41 RR002305-246021 · United States
NIA NIH HHS · R01 AG014971 · United States
NIA NIH HHS · R01 AG014971-09 · United States
NCRR NIH HHS · P41 RR002305-236875 · United States
NCRR NIH HHS · P41 RR002305-255549 · United States
NCRR NIH HHS · P41 RR002305 · United States
NIA NIH HHS · R01 AG014971-08 · United States
External Links
PubMed source DOI: 10.1159/000109754 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2